Conclusion: in contemporary practice of treatment of myocardial infarction, beta-blockers have no mortality benefit but reduce recurrent myocardial infarction and angina (short-term) at the expense of increase in heart failure, cardiogenic shock , and drug discontinuation. The guideline authors should reconsider the strength of recommendations for beta-blockers post myocardial infarction